+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Selection of lower cutoff point of [13C]urea breath test is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy



Selection of lower cutoff point of [13C]urea breath test is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy



Digestive Diseases and Sciences 45(7): 1330-1336



Our objectives were to test the efficacy of [13C] urea breath test (UBT) for H. pylori infection in patients before and after proton pump inhibitor (PPI) based triple therapy, and thus to trace the optimal cutoff value of UBT to monitor H. pylori eradication; and to analyze the histologic bacterial density and distribution of H. pylori in patients with equivocal UBT. A total of 441 dyspeptic cases patients enrolled and completed the study design, including 120 noninfected and 321 H. pylori-infected patients. All 441 cases had received the same protocol of UBT. in which the baseline and 15-min gas samples after ingestion of 100 mg 13C-labeled urea were analyzed for excess 13CO2/12CO2 ratio (ECR). In addition, a first endoscopy was performed in each patient to evaluate the initial status of H. pylori by culture and histology. Of the 321 H. pylori-infected patients, 286 received a second endoscopy and a second UBT six weeks after completing any one of four regimens of the PPI-based triple therapy to document the success of H. pylori eradication. During both sessions of endoscopy, topographic gastric biopsies for histology were sampled to evaluate the distribution and density of H. pylori. Based on the diagnostic standard by culture and histology, the sensitivity and specificity of the first UBT achieved most optimally was 97.5% and 96.7%, respectively, by setting the cutoff point of ECR at 4.0. In contrast, using the same cutoff point of 4.0, the sensitivity and specificity of the second UBT in patients after therapy achieved just 80% and 97.6%, respectively. By applying cutoff points downward of 4.0, 3.5, 3, and 2.5 for the second UBT, the sensitivity was elevated to 80%, 82.8%, 88.6%, and 94.3%, respectively, while the specificity was preserved at more than 95.2%. The overall eradication rate of H. pylori was 87.8% (251/286). Seven of 35 patients with failure of therapy had equivocal ECR at the second UBT (range 2-5), and this accounted for the false negative result. All seven patients had low bacterial densities, and three patients had bacteria distributed only in high body near the cardia. In conclusion, selection of a lower cutoff value of ECR at 2.5 is helpful to maintain the diagnostic accuracy of UBT for monitoring the H. pylori eradication. The equivocal ECR of UBT after therapy would be related to the low bacterial load and its distribution.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047325766

Download citation: RISBibTeXText

PMID: 10961711

DOI: 10.1023/a:1005599818959


Related references

A lower cut-off point of 13C urea breath test is more suitable to monitor the success of H pylori eradication. Gut 45(SUPPL 3): A125, Sept, 1999

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Annals of Clinical Microbiology and Antimicrobials 17(1): 29, 2018

Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiology and Drug Safety 23(5): 443-455, 2014

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Alimentary Pharmacology & Therapeutics 13(2): 163-168, 1999

One or two weeks of a Proton Pump Inhibitor-Based Triple therapy for Helicobacter pylori eradication?. Gut 51(Supplement 2): A63-A64, 2002

Addition of clidinium-C to the 14-day proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication. Caspian Journal of Internal Medicine 7(2): 78-81, 2016

Addition of cranberry to proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Journal of Research in Pharmacy Practice 5(4): 248-251, 2016

Eradication of Helicobacter pylori infection with proton pump inhibitor-based triple therapy. A randomised study. Panminerva Medica 44(2): 145-147, 2002

Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children. Pediatric Gastroenterology, Hepatology and Nutrition 15(4): 237-242, 2013

Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication. Annals of Internal Medicine 147(8): 553-562, 2007

One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. World Journal of Gastroenterology 11(11): 1680-1684, 2005

Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?. American Journal of Gastroenterology 96(2): 359-366, 2001

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. Journal of Clinical Biochemistry and Nutrition 47(1): 53-58, 2010

Patients factors, DOB value of 13C-urea breath test and clinical diagnosis do not affect eradication of Helicobacter pylori with omeprazole based triple therapy. Gut 49(Supplement 11): A95, 2001

Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Zhonghua Yi Xue Za Zhi 88(38): 2722-2725, 2009